Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: OSZCZAPOWICZ
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Amifostyna - nowoczesny cytoprotektor.
Tytuł angielski: Amifostin - modern cytoprotector.
Autorzy: Wąsowska Małgorzata, Oszczapowicz Irena
Źródło: Farm. Pol. 2002: 58 (22) s.1053-1059, il., bibliogr. 16 poz., sum.
Sygnatura GBL: 310,851

Hasła klasyfikacyjne GBL:
  • toksykologia
  • farmacja

    Typ dokumentu:
  • praca kliniczna

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Amifostin (Ethynol, Ethiofos, Ethanetiol, Gammaphos) is a cytoprotector capable of protecting tissue against toxic effects of alkylating agents and/or radiation, without adversely affecting tumour response or patient survival. These adverse effects include myelosuppresion or hematological toxicity, neurotoxicity and nephrotoxicity. Amifostin, being organic thiophosphate, is dephosporylated to the active free thiol metabolite by a cell-bound alkaline phosphatase either not prresent in tumors or not active in the low pH found in tumours. The free thiol is transported selectively into normal cells where it is able to bind and inactivate the species of alkylating agents. A maximum - tolerated dose of this cytoprotector ranges from 740 to 910 mg/m2. Amifostin is generally well tolerated but it is associated with such side effects as hypotension, nausea, vomiting, sneezing, mild somnolence, a metalic taste during infusion, and allergic reactions. Amifostin should be administered IV over 15 minutes to patients in reclining position and should be given within 30 minutes of chemotherapy or radiation therapy. Human pharmacokinetic studies suggest, that the plasma half-life of amifostine is about 1 minute and that virtually all of the drug is cleared from the plasma-life within 10 minutes.

    stosując format: